Aster DM Healthcare Limited — PPTs, 20-05-2025: Investor Presentation

1. Financial Highlights:

Aster DM Healthcare reported revenue of INR 1,000 Cr (+2% YoY) and operating EBITDA of INR 193 Cr (+16% YoY), with EBITDA margin expanding to 19.3%. Annual revenue grew 12% to INR 4,138 Cr and EBITDA surged 30% to INR 806 Cr, margin at 19.5%. Normalized PAT rose 21% quarterly to INR 106 Cr and 49% annually to INR 357 Cr. ARPOB improved 13% QoQ to INR 47,800, with steady occupancy (~65%) and shorter average length of stay. Net debt and lease liabilities to equity is a low 0.2x, while ROCE improved to 19.5% from 16.4%.

2. Strategic Initiatives & Growth Drivers:

The company added ~300 beds this year and plans 2,100+ more by FY27 to reach ~7,300 beds. Key greenfield projects in Trivandrum (454 beds), Hyderabad (300 beds), and Kasargod (264 beds) are progressing. Oncology focus intensifies with India’s first IOeRT machine plus investments in robotics and transplants. The Aster Health app crossed 24,000 downloads in one month, boosting patient engagement and care delivery.

3. Business Developments:

The Quality Care (QCIL) merger is advancing, with regulatory and shareholder approvals done, share swap completed, and NCLT approval ongoing. QCIL’s FY25 revenue stood at INR 3,967 Cr with EBITDA of INR 813 Cr. Synergies of 10-15% EBITDA upside are expected from procurement, doctor integration, and overhead optimization. Facility upgrades continue across QCIL units.

4. Market Position & Competitive Advantage:

Aster leads in South India with 19 hospitals, 262 labs, and 203 pharmacies in 15 cities. Mature assets deliver strong 24.3% EBITDA margins and 33.7% ROCE. Specialty services span cardiac, neuro, oncology, joint replacement, and robotic surgeries, backed by advanced technology and clinical expertise. Awards for hospital quality and workplace culture boost brand strength.

5. Investor Implications:

Capacity expansion, margin improvement, and high-margin specialty growth underpin positive growth potential. QCIL merger promises synergy-driven scale benefits and stronger market position. Execution risk centers on capital project timelines and integration but digital and clinical innovation offer profitability levers. Key factors to watch: bed additions and synergy delivery.